Liver Failure Clinical Trial
Official title:
Phase Ⅰ/Ⅱ Study of Human Umbilical Cord Derived Mesenchymal Stem Cells (UC-MSCs) for Treatment of Liver Failure
Liver failure (LF) is a dramatic clinical syndrome with massive necrosis of liver cells. and liver transplantation is the only available therapeutic option for patients suffering with this condition. However, lack of donors, surgical complications, rejection, and high cost are serious problems. Previous study showed that bone marrow derived mesenchymal stem cells (BM-MSCs) replace hepatocytes in injured liver, and effectively rescue experimental liver failure and contribute to liver regeneration. In this study, the patients with LF will undergo administration of human umbilical cord mesenchymal stem cells (UC-MSCs) via peripheral vein transfusion to evaluate the safty and efficacy of UC-MSCs treatment for these patients.
Liver failure (LF) is a severe life-threatening condition, and is a dramatic clinical syndrome with massive necrosis of liver cells, and liver transplantation is the only available therapeutic option for patients suffering with this condition. However, lack of donors, surgical complications, rejection, and high cost are serious problems. Since current therapeutic options for LF that is usually with extremely poor prognosis are still limited, recent studies indicate that mesenchymal stem cells (MSCs), due to their function in immune modulation and liver-damage repair, are of great therapeutic potential for this disease. Previous study showed that bone marrow derived mesenchymal stem cells (BM-MSCs) replace hepatocytes in injured liver, and effectively rescue experimental liver failure and contribute to liver regeneration.The purpose of this study is to investigate the safety and initial efficacy of human umbilical cord MSC (UC-MSCs) treatment for patients with LF. In this study, MSCs were isolated from umbilical cord and generated in appropriate growth medium. 50 LF patients with LF received i.v. transfusion of 0.5-1.0×106 cells/kg of MSCs as the treated group and other 20 LF patients with LF were transfused with placebo without MSCs as control group. All 70 of them received the routine management for liver failure. During the 2-year follow up, the evaluation of safty and efficacy will be undergone to help to establish innovative cell-based therapies for the treatment of diseases. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03791190 -
RCA for CRRT in Liver Failure and High Risk Bleeding Patients
|
N/A | |
| Recruiting |
NCT05989958 -
The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure
|
Phase 1 | |
| Completed |
NCT02557724 -
Mobilization of Mesenchymal Stem Cells During Liver Transplantation
|
||
| Recruiting |
NCT01698723 -
A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus
|
Phase 2 | |
| Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
| Completed |
NCT01404793 -
SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation
|
N/A | |
| Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
| Completed |
NCT03864497 -
Myocardial Perfusion Imaging in Liver Transplantation Candidates
|
||
| Completed |
NCT00287235 -
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
|
N/A | |
| Completed |
NCT03650920 -
Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients
|
N/A | |
| Recruiting |
NCT05517668 -
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
|
Phase 2 | |
| Recruiting |
NCT05726032 -
Empagliflozin in Patients With Cirrhosis and Ascites
|
Phase 2 | |
| Recruiting |
NCT04548596 -
NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
|
||
| Recruiting |
NCT02331745 -
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
|
Phase 4 | |
| Not yet recruiting |
NCT01961440 -
Prognosis Scoring System for Acute-on-Chronic Liver Failure
|
N/A | |
| Active, not recruiting |
NCT01221454 -
Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure
|
Phase 2 | |
| Completed |
NCT00772148 -
Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients
|
Phase 2 | |
| Completed |
NCT05592106 -
Gd-EOB-DTPA-enhanced T1 Map for Predicting Postoperative Liver Failure
|
||
| Not yet recruiting |
NCT06014320 -
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
|
||
| Recruiting |
NCT04221672 -
The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy
|
Phase 3 |